Pregnenolone for the Treatment of Alcohol Use Disorder

Last updated: February 20, 2025
Sponsor: Yale University
Overall Status: Active - Recruiting

Phase

2

Condition

Alcohol Use Disorder

Alcohol Dependence

Addictions

Treatment

Pregnenolone

Placebo

Clinical Study ID

NCT05781009
2000034929
1R01AA030923-01
R01AA030923
  • Ages 18-70
  • All Genders

Study Summary

This Phase 2 randomized cotrolled trial (RCT) will assess the safety and efficacy of pregnenolone (PREG; 300 mg/day, b.i.d dosing) vs. placebo (PBO) over a 12 week treatment period, and at 1-month post-treatment follow-up in individuals with Alcohol Use Disorder (AUD).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male and females, aged 18-70 years;

  • Regular weekly use of alcohol at least 3X weekly or more at treatment entry;

  • Must meet current DSM-5 criteria for moderate to severe Alcohol Use Disorders (AUDs)using SCID-I for DSM-5;

  • No health conditions that would impact trial participation as verified by screeningand physical examination and absence of any of the exclusion criterions outlinedbelow;

  • Able to read English and complete study evaluations;

  • Able to provide informed written and verbal consent.

Exclusion

Exclusion Criteria:

  • Meet current criteria for moderate to severe substance use disorders from use of anyother psychoactive substance, excluding nicotine and cannabis use disorder;

  • Current use of opioids;

  • Regular use of anticonvulsants, sedatives or hypnotics, oral prescription analgesics (other than non-steroidal anti-inflammatory drugs), topiramate, baclofen;

  • Regular use of steroidal supplements and steroid medications interacting with studymedications based on clinical judgement of study physician (excluding hormonalcontraceptives in women);

  • Psychotic or otherwise severely psychiatrically disabled (i.e., suicidal, homicidal,current mania);

  • Significant underlying medical conditions such as cerebral, renal, thyroid orcardiac pathology which in the opinion of study physician would preclude patientfrom fully cooperating or be of potential harm during the course of the study, butstable, prescribed anti-hypertensives. cardiovascular and diabetes medications willbe allowed after review by study physician;

  • Any psychotic disorder or current Axis I psychiatric disorders requiring specificacute attention, including need for psychiatric medications, but stable, prescribedantidepressants and anti-anxiety medication to treat co-occurring psychiatricdisorders will be allowed;

  • Women who are pregnant, nursing or refuse to use a reliable form of birth control (as assessed by urine pregnancy tests during initial medical evaluation, andassessed every two weeks during the course of the study).

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Pregnenolone
Phase: 2
Study Start date:
January 08, 2024
Estimated Completion Date:
July 31, 2028

Study Description

In this Phase 2 single-site randomized controlled trial (RCT), men and women with Alcohol Use Disorder (AUD) will be enrolled in a 12 week trial with a 1-month follow-up assessment. Participants will be randomly assigned to 300mg pregnenolone (PREG) treatment b.i.d., or Placebo (PBO). All participants will be assessed 2x weekly and also receive behavior counseling to support recovery. The study aims to examine a) the safety and tolerability; b) efficacy on alcohol use outcomes; and c) effects on alcohol craving, anxiety, depression and physical well-being of 300mg PREG vs. PBO in men and women with AUD over the 12-week treatment period and at the 1-month follow up post-treatment period.

Connect with a study center

  • The Yale Stress Center: Yale University

    New Haven, Connecticut 06519
    United States

    Active - Recruiting

  • Yale Stress Center

    New Haven, Connecticut 06519
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.